120 related articles for article (PubMed ID: 37913791)
21. DaBlaCa-17: nationwide observational study in Denmark on survival before and after implementation of neoadjuvant chemotherapy prior to cystectomy for muscle-invasive bladder cancer.
Körner SK; Dreyer T; Carus A; Dohn LH; Joensen UN; Lam GW; Jensen NV; Fabrin K; Jensen TK; Pappot H; Agerbæk M; Jensen JB
Scand J Urol; 2024 Feb; 59():39-46. PubMed ID: 38406925
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant versus Adjuvant Chemotherapy in Patients with Resectable Muscle-Invasive Bladder Cancer.
Sawasdee A; Tanthanuch M; Bejrananda T
Asian Pac J Cancer Prev; 2022 Nov; 23(11):3641-3647. PubMed ID: 36444575
[TBL] [Abstract][Full Text] [Related]
23. The increased risk for thromboembolism pre-cystectomy in patients undergoing neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer is mainly due to central venous access: a multicenter evaluation.
Ottosson K; Pelander S; Johansson M; Huge Y; Aljabery F; Sherif A
Int Urol Nephrol; 2020 Apr; 52(4):661-669. PubMed ID: 31745708
[TBL] [Abstract][Full Text] [Related]
24. Sarcopenia and Response to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.
Lyon TD; Frank I; Takahashi N; Boorjian SA; Moynagh MR; Shah PH; Tarrell RF; Cheville JC; Viers BR; Tollefson MK
Clin Genitourin Cancer; 2019 Jun; 17(3):216-222.e5. PubMed ID: 31060857
[TBL] [Abstract][Full Text] [Related]
25. The role of neoadjuvant chemotherapy for patients with variant histology muscle invasive bladder cancer undergoing robotic cystectomy: Data from the International Robotic Cystectomy Consortium.
Cooke I; Abou Heidar N; Mahmood AW; Ahmad A; Jing Z; Stöckle M; Wagner AA; Roupret M; Kim E; Vasdev N; Balbay D; Rha KH; Aboumohamed A; Dasgupta P; Maatman TJ; Richstone L; Wiklund P; Gaboardi F; Li Q; Hussein AA; Guru K
Urol Oncol; 2024 Apr; 42(4):117.e17-117.e25. PubMed ID: 38429124
[TBL] [Abstract][Full Text] [Related]
26. Association between the Absolute Baseline Lymphocyte Count and Response to Neoadjuvant Platinum-based Chemotherapy in Muscle-invasive Bladder Cancer.
Leibowitz-Amit R; Israel A; Gal M; Atenafu EA; Symon Z; Portnoy O; Laufer M; Dotan Z; Ramon J; Avni D; Fridman E; Berger R
Clin Oncol (R Coll Radiol); 2016 Dec; 28(12):790-796. PubMed ID: 27498850
[TBL] [Abstract][Full Text] [Related]
27. A population-based retrospective analysis on variation in use of neoadjuvant chemotherapy depending on comorbidity in patients with muscle-invasive bladder cancer undergoing cystectomy in Denmark in the period 2013-2019.
Körner SK; Jensen JB
Scand J Urol; 2022 Feb; 56(1):34-38. PubMed ID: 34775886
[TBL] [Abstract][Full Text] [Related]
28. Persistent muscle-invasive bladder cancer after neoadjuvant chemotherapy: an analysis of Surveillance, Epidemiology and End Results-Medicare data.
Lane G; Risk M; Fan Y; Krishna S; Konety B
BJU Int; 2019 May; 123(5):818-825. PubMed ID: 30126053
[TBL] [Abstract][Full Text] [Related]
29. Residual CIS after neoadjuvant chemotherapy and radical cystectomy for muscle invasive bladder cancer: Implications for neoadjuvant trials.
Gabrielson AT; Daniels MJ; Rowe J; Alam R; Lee EJ; Matoso A; De Felice A; Hahn N; Hoffman-Censits J; Bivalacqua TJ; Kates M
Urol Oncol; 2022 Apr; 40(4):164.e9-164.e16. PubMed ID: 35045949
[TBL] [Abstract][Full Text] [Related]
30. A risk-stratified approach to neoadjuvant chemotherapy in muscle-invasive bladder cancer: implications for patients classified with low-risk disease.
Lyon TD; Frank I; Sharma V; Shah PH; Tollefson MK; Thompson RH; Karnes RJ; Thapa P; Cheville JC; Boorjian SA
World J Urol; 2019 Aug; 37(8):1605-1613. PubMed ID: 30392012
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings.
Rose TL; Deal AM; Basch E; Godley PA; Rathmell WK; Kim WY; Whang YE; Dunn MW; Wang A; Chen RC; Nielsen ME; Pruthi RS; Wallen EM; Woods ME; Smith AB; Milowsky MI
Urol Oncol; 2015 Sep; 33(9):386.e1-6. PubMed ID: 26122712
[TBL] [Abstract][Full Text] [Related]
32. Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI.
Woo S; Becker AS; Das JP; Ghafoor S; Arita Y; Benfante N; Gangai N; Teo MY; Goh AC; Vargas HA
Cancer Imaging; 2023 Nov; 23(1):110. PubMed ID: 37964386
[TBL] [Abstract][Full Text] [Related]
33. The role of neoadjuvant chemotherapy, lymph node dissection, and treatment delay in patients with muscle-invasive bladder cancer undergoing partial cystectomy.
Lenis AT; Fero KE; Ojeaburu L; Lec PM; Golla V; Brisbane W; Leapman MS; Chamie K
Urol Oncol; 2021 Aug; 39(8):496.e17-496.e24. PubMed ID: 33640225
[TBL] [Abstract][Full Text] [Related]
34. Downstaging and survival after Neoadjuvant chemotherapy for bladder cancer in Norway; a population-based study.
Møller CT; Støer NC; Blindheim A; Berge V; Tafjord G; Fosså SD; Andreassen BK
BMC Cancer; 2022 Dec; 22(1):1301. PubMed ID: 36510166
[TBL] [Abstract][Full Text] [Related]
35. Survival outcomes of patients with muscle-invasive bladder cancer according to pathological response at radical cystectomy with or without neo-adjuvant chemotherapy: a case-control matching study.
van Ginkel N; Hermans TJN; Meijer D; Boormans JL; Voortman J; Mertens L; van Beek SC; Vis AN;
Int Urol Nephrol; 2022 Dec; 54(12):3145-3152. PubMed ID: 35997906
[TBL] [Abstract][Full Text] [Related]
36. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy.
Culp SH; Dickstein RJ; Grossman HB; Pretzsch SM; Porten S; Daneshmand S; Cai J; Groshen S; Siefker-Radtke A; Millikan RE; Czerniak B; Navai N; Wszolek MF; Kamat AM; Dinney CP
J Urol; 2014 Jan; 191(1):40-7. PubMed ID: 23911605
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
Osanto S; Álvarez Gómez de Segura C
Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
[TBL] [Abstract][Full Text] [Related]
38. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.
Chakiryan NH; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain R; Chahoud J; Poch M; Manley BJ; Li R; Sexton W; Gilbert SM
J Urol; 2021 Oct; 206(4):924-932. PubMed ID: 34032503
[TBL] [Abstract][Full Text] [Related]
39. The utilization status of neoadjuvant chemotherapy in muscle-invasive bladder cancer: a systematic review and meta-analysis.
Liu W; Tian J; Zhang S; Yang E; Shen H; Li F; Li K; Zhang T; Wang H; Svatek RS; Rodriguez R; Wang Z
Minerva Urol Nephrol; 2021 Apr; 73(2):144-153. PubMed ID: 31920065
[TBL] [Abstract][Full Text] [Related]
40. Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer.
van Hoogstraten LMC; Man CCO; Witjes JA; Meijer RP; Mulder SF; Smilde TJ; Ripping TM; Kiemeney LA; Aben KKH;
World J Urol; 2023 Jul; 41(7):1837-1845. PubMed ID: 37258902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
